科兴制药引进产品——贝伐珠单抗在玻利维亚获批上市

Core Viewpoint - Recently, Sinovac Biotech (688136.SH) has received approval from Bolivia's National Medicines and Health Technologies Authority (AGEMED) for its biosimilar product, Bevacizumab, marking the fifth country where this product has been approved following its collaboration with Easton Pharmaceutical [1] Group 1: Product Approval and Market Expansion - Bevacizumab is a commonly used drug in oncology, applicable for various cancers including metastatic colorectal cancer, advanced/metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian cancer, tubal cancer, primary peritoneal cancer, and cervical cancer [1] - The approval in Bolivia is part of a broader trend, as Sinovac's pharmaceutical exports to emerging markets such as ASEAN, Latin America, and Africa are steadily increasing, with Latin America seeing an 11.4% growth [1] - Sinovac has established a subsidiary in Latin America and formed a localized operational team to enhance market penetration and improve drug accessibility in the region [1] Group 2: International Registration Progress - Since the beginning of this year, multiple Sinovac products have received market approval in various countries, with Bevacizumab biosimilar already registered in five countries including Pakistan and Indonesia [1] - There are over twenty additional countries where registration efforts for the product are rapidly advancing [1]